101 
Market Cap
Stock Chart
Novogen - 30 Day Poll
Recent BLOGS About Novogen Add New
Latest Company News
|
First Novogen breeding stock in Japan
WorldPoultry.net - 6 hours ago The first Novogen breeding stock has arrived in Japan. This is a very important market for layer breeders with around 1.3 mln parents being placed. At present the market requirement is split ...
|
|
Novogen Limited Receives Nasdaq Notice
MarketWatch - Jul 23, 2010 SYDNEY, AUSTRALIA, Jul 23, 2010 (MARKETWIRE via COMTEX) -- Novogen Limited (ASX: NRT) (NASDAQ:NVGN) is listed on the Australian Stock Exchange and has an ADR program in place in the US through the ...
|
|
Novogen appoints new CFO
CFO World - Jun 21, 2010 By CFO World Staff (CFO World) Aussie biotechnology company, Novogen Limited (ASX: NRT) has announced the appointment of Mark Hinze as the company's new CFO and Operations manager. Hinze has been ...
|
|
Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
MarketWatch - Jun 18, 2010 SYDNEY, AUSTRALIA, Jun 18, 2010 (MARKETWIRE via COMTEX) -- Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ:MSHL) , has announced today the appointment of Mr. Thomas Zech as its CFO ...
Marshall Edwards (MSHL) Appoints Thomas Zech as CFO; Other Changes Announced - StreetInsider.comMarshall Edwards Inc. Names Thomas Zech CFO And Company Secretary - Quick Facts - Stock Markets Review |
|
Australia’s Marshall Edwards says final Ph III results of phenoxodiol disappoint
The Pharma Letter - Jun 3, 2010 Australia-based Marshall Edwards, which is majority owned by Australian biotechnology firm Novogen, says that a final analysis of its Phase III OVATURE trial of orally administered phenoxodiol in ...
Marshall Edwards' CEO to Present at Needham Healthcare Conference - Trading Markets |
|
Top Losers For Your Watch List (VSR, NVGN, Canadian Solar Inc., SNIC, IFLG)
Emailwire - Jun 3, 2010 (EMAILWIRE.COM, June 03, 2010 ) Springfield, VA - Versar Inc. (Public, AMEX:VSR) Ended the day down 8.83% at 3.51 on unusual volume of 642,072 shares above it's average volume of 88,768 shares ...
|
|
Outlook: Strong start likely for Aussie stocks
Finance News Network - Jun 2, 2010 Following a strong lead from Wall St overnight, the Australian share market is likely to open higher today. US stocks rallied overnight driven by a surge in energy stocks as investor confidence ...
|
|
Amgen, Alexion climb; Novogen sinks
Middle East North Africa Financial Network - Jun 2, 2010 By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Drugs stocks trended higher in early trading Wednesday, with Amgen Inc. and Alexion Pharmaceuticals taking the lead. Shares of Amgen ...
|
Website
Videos related to Novogen
Company Profile
Cash on hand: A$32.3 million as of 30th June 2009
Novogen is based on a family of naturally-occurring plant compounds known as flavonoids which are important and primitive regulators of such basic functions of cells in Nature as how they survive and maintain normal vigor and then die at a predetermined time. Such effects occur also in human cells and humans consume flavonoids in such substantial quantities.
The company has Phase I, Phase II & Phase III (for cervical cancer) compounds. General areas of focus include:
- Cancer
- Heart disease (stroke, hypertension, coronary artery disease)
- Osteoporosis
- Chronic inflamatory diseases (rheumatoid arthritis, osteoarthritis, chronic back pain)
- Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease)
Novogen is addressing this area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the prospect of not only treating, but also preventing, the onset of these common degenerative conditions. And includes at l;east 2 divisions:
1. Pharmaceutical division – developing an extensive portfolio of prescription drugs
2. Consumer health division – developing a range of non-prescription products meeting important health needs of men and women